Pfizer and BioNTech Begin Phase 1/2 Trial for COVID-19 Vaccine
- Posted by ISPE Boston
- On May 6, 2020
Pfizer and BioNTech have dosed the first participants in the U.S. and Germany in the Phase 1/2 clinical trial for the BNT162 COVID-19 vaccine program. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. Pfizer and BioNTech’s development […]
Read More